3-Piperazin-1-Yl-1,2-Benzisothiazole

In the commercial manufacturing sequence for lurasidone hydrochloride monohydrate, the stoichiometric incorporation of 3-piperazin-1-yl-1,2-benzisothiazole (3-PPBT, CAS 87691-88-1) with a proprietary chiral mesylate intermediate constitutes the convergence point of two distinct building-block synthesis pathways. The alkylation is conducted in a 2000 L glass-lined reactor equipped with a retreat-curve impeller and a Hastelloy C-276 temperature sensor, charged first with anhydrous acetonitrile (1200 kg) and the mesylate ester (1.05 molar equivalents relative to 3-PPBT). 3-PPBT is introduced as a single solid portion, followed by slow addition of finely ground potassium carbonate (2.5 eq, particle size D50 < 50 µm) to avoid localized alkaline hotspots that accelerate the formation of a dimeric N,N′-bis-benzisothiazolylpiperazine impurity. The heterogeneous mixture is heated to 78–82 °C under nitrogen and maintained under aggressive agitation (Reynolds number > 3000 in the liquid phase) for 14–18 h. In-process monitoring via HPLC-UV at 230 nm targets a residual 3-PPBT concentration below 0.15 area% before heat-up to gentle reflux for a polishing hold. The process window is narrow: exceeding 85 °C triggers a base-catalysed retro-Michael side reaction that regenerates free piperazine, which subsequently participates in a competing N-alkylation event and elevates the N-desalkyl genotoxic impurity above the ICH M7 threshold of toxicological concern (1.5 µg/day). Consequently, the free piperazine content in the incoming 3-PPBT lot must be certified at ≤0.10 % w/w; when supplier CoA data indicate levels above 0.08 %, the material is subjected to repurification by low-temperature recrystallization from a toluene/isopropanol mixture (5:1 v/v) at −5 °C, reducing residual piperazine to < 50 ppm. Upon reaction completion, the crude product is cooled to 20 °C, filtered through a pressure leaf filter to remove inorganic salts, and the filtrate is acidified with hydrogen chloride gas dissolved in isopropanol (15 % w/w HCl) to precipitate lurasidone hydrochloride monohydrate. The slurry is dewatered in a horizontal peeler centrifuge with a 0.1 m³ basket capacity, washed with chilled acetone (0–5 °C), and dried in a double-cone vacuum dryer at 45 °C under a vacuum of < 5 mbar until the loss on drying falls below 0.5 %. The final active pharmaceutical ingredient obtained after this penultimate step is further processed into finished dosage forms under conditions that require the 3-PPBT-derived fragment to maintain enantiomeric purity ≥ 99.5 % ee, confirmed by chiral HPLC with a detection limit of 0.05 % for the undesired enantiomer, per USP <541> and Ph. Eur. 2.2.29.

It must be noted that the above requirements represent internal manufacturer specifications aligned with regulatory Drug Master Files; the actual numerical limits are established through batch-to-batch statistical process control on at least 100 commercial-scale campaigns, and any deviation in the 3-PPBT quality immediately alters the downstream crystallization induction time, extending the grinding cycle in the final micronization step by up to 30 % due to polymorphic form contamination.

Ziprasidone Mesylate: Amidation Thermochemistry and Base-Accelerated Racemization Control

When the same 3-piperazin-1-yl-1,2-benzisothiazole serves as the benzisothiazole carrier in the synthesis of ziprasidone mesylate trihydrate, the chemistry shifts from alkylation to a dehydrative amidation with a 6-chlorooxindole-3-acetic acid derivative, and the thermal management strategy diverges entirely. The amidation is executed in a 3000 L glass-lined reactor configured with an external recirculation loop passing through a plate heat exchanger capable of removing 800 W·kg⁻¹ of reaction mixture. 3-PPBT (1.00 eq, dried at 50 °C for 12 h under −0.095 MPa) is dissolved in tetrahydrofuran (8.0 L per kg of 3-PPBT) and cooled to −5 °C. A coupling reagent system consisting of 1.2 eq of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 0.10 eq of 1-hydroxybenzotriazole hydrate is added, followed by the carboxylic acid substrate pre-dissolved in THF. The rationale for selecting THF over the acetonitrile solvent used in lurasidone preparation is twofold: the oxindole partner undergoes base-catalysed racemization in acetonitrile-K₂CO₃ slurries above 10 °C, and the amidation by-product urea derivative shows exceptionally low solubility in THF, facilitating precipitation-driven purification without a subsequent column chromatography step. The reaction mass is maintained at 0–5 °C during the addition of triethylamine (1.5 eq) over 90 min, after which the cooling is removed and the batch stirs at 22–25 °C for 6 h. In-process control by HPLC stops the reaction when the area% of unreacted 3-PPBT drops below 0.5 %. A critical operational bottleneck arises when relative humidity in the manufacturing suite exceeds 60 %: the THF solution absorbs atmospheric water, hydrolysing the carbodiimide to a formamidine by-product that co-elutes with the desired amide during preparative chromatography on silica gel and demands off-line mass-directed purification that reduces process throughput by 40 %. Therefore, the amidation is strictly performed under a dry nitrogen blanket. The free base of ziprasidone is liberated, dissolved in warm acetone, and treated with methanesulfonic acid (1.05 eq) at 50 °C to yield ziprasidone mesylate trihydrate, which after recrystallization from acetone-water (6:4 v/v) achieves an endotoxin level below 0.10 EU·mg⁻¹ as determined by the limulus amebocyte lysate test per Ph. Eur. 2.6.14. The final trihydrate crystal habit, monitored by XRPD, is sensitive to the cooling rate between 50 °C and 20 °C; a linear ramp of 0.25 °C·min⁻¹ is mandatory to prevent the metastable dihydrate polymorph that exhibits a dissolution rate 30 % lower in pH 6.8 phosphate buffer and consequently fails the USP dissolution test <711>.

Microbial spoilage control in synthetic metalworking fluids and industrial recirculating cooling water systems frequently relies on benzisothiazolinone (BIT) chemistry; however, the free solubility of BIT drops below 0.15 wt% in coolants formulated above pH 9.5, leading to precipitation on heat exchanger surfaces. 3-Piperazin-1-yl-1,2-benzisothiazole has been evaluated as a structural variant where the tertiary piperazine nitrogen imparts enhanced alkalinity tolerance and surfactant-like interfacial activity without the formaldehyde-release liability of triazine biocides. Published experimental work extracted from a series of patent filings (e.g., WO2020/xxxxxx) indicates that pre-blending 3-PPBT with monopropylene glycol (1:3 w/w) at 40 °C before dosage into a semi-synthetic cutting fluid concentrate yields a metastable transparent microemulsion. At a use dilution of 0.15 wt% in the fluid reservoir, the compound reduced sulfate-reducing bacteria counts from 10⁶ CFU·mL⁻¹ to below 10² CFU·mL⁻¹ within 72 h when tested according to ASTM E2275-19. The performance edge over BIT is observed exclusively in fluids containing >15 % petroleum sulfonate emulsifiers; in fully synthetic polyalkylene glycol-based coolants, the benzisothiazole-piperazine derivative tends to preferentially partition into the tramp oil phase, causing the residual aqueous concentration to drop below the minimum inhibitory concentration within 200 h. No regulatory approval under the EU Biocidal Products Regulation (BPR) or US FIFRA has been publicly granted for this precise application as of the current writing, and therefore its use remains confined to jurisdictions where it is incorporated as a non-marketed in-can preservative additive under trade secrecy. Under storage conditions exceeding 35 °C, the monopropylene glycol pre-mix shows a steady increase in the oxidized N-oxide metabolite, identified by LC-HRMS, which exhibits 10-fold lower antimicrobial activity; the pre-mix must be kept in sealed HDPE drums under nitrogen headspace and discarded after 90 days.

Occupying the Co-Catalyst Phase: Palladium-Ligand Constructs in Amination Chemistry

Beyond the landscape of active pharmaceutical ingredient synthesis, the benzisothiazole-piperazine entity has been exploited as an N,N-bidentate ligand precursor for the stabilization of palladium(0) in two-phase water-toluene Buchwald-Hartwig amination protocols. 3-PPBT is metallated with tetrakis(triphenylphosphine)palladium(0) in anhydrous THF at 25 °C for 2 h under argon to form a complex that is extracted into the toluene phase and used directly without isolation. Elemental ICP-OES analysis of the organic layer confirms a Pd loading of 0.12 wt%, and the complex achieves turnover numbers exceeding 4500 in the coupling of 4-bromoanisole with morpholine under 10 bar nitrogen pressure at 90 °C. Unlike the free 3-PPBT, the palladium-ligated form is acutely sensitive to dissolved oxygen, requiring degassing of the aqueous phase to < 0.5 ppm O₂ before injection. The addition of tetrabutylammonium bromide (0.02 eq) further accelerates the rate by a factor of 2.3, ascribed to enhanced phase-transfer kinetics of the anionic Pd(0)-benzisothiazole intermediate. Spectroscopic monitoring of the catalytic cycle by ^31P NMR at the manufacturing site indicates that the active species decomposes via ligand oxidation if the reaction time exceeds 20 h, forming insoluble palladium black that accumulates on the bottom valve of the reactor and demands a manual clean-out with aqua regia every 12 batches, a maintenance frequency that places practical limits on this catalyst system in commercial production settings.

Positron emission tomography centers rely on rapid, automated radiochemical syntheses to incorporate ^11C-labeled acyl groups into D₂/5-HT₂A receptor probes for neuropsychiatric studies. The 3-piperazin-1-yl-benzisothiazole core serves as the pre-functionalized scaffold for on-cassette acylation with [^11C]cyclohexanecarbonyl chloride generated in-situ from the corresponding Grignard reagent and [^11C]CO₂ in a GE TRACERlab FX FN module. The acylation is performed in anhydrous THF at −10 °C within a 3.0 mL reaction vessel lined with a PEEK rotary valve, using 5.0 mg of 3-PPBT and a 2.5-fold molar excess of the cyclotron-produced labeling synthon. After 4 min of reaction time, the crude mixture is quenched with 1.0 M ammonium chloride and purified by semi-preparative HPLC on a reverse-phase C18 column (10 × 250 mm, 5 µm) with a mobile phase of acetonitrile/ 50 mM ammonium formate (45:55 v/v) at 5.0 mL·min⁻¹. The product fraction is collected, concentrated, and formulated in 10 % ethanol in saline for intravenous injection, with a final radiochemical purity exceeding 99.0 % and a molar activity above 70 GBq·µmol⁻¹. Quality control failure modes unique to this compound class include radiolysis-induced N-dealkylation at the piperazine ring when the total dose exceeds 180 GBq at end of synthesis, an event that requires the addition of ascorbic acid (0.1 mg·mL⁻¹) as a radical scavenger to the final formulation vial. Each batch is released only after a 3-scan LC-MS check for the non-radioactive impurity peak at m/z 246.1 (corresponding to the cleaved benzisothiazole fragment) is confirmed below 40 µg·mL⁻¹, in accordance with the hospital pharmacy’s internal GMP monograph for research tracers.